First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity ...
Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer ...
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial ...
Arun Nathani, CEO and Managing Director of Cybage Software, a global leader in Digital Engineering Services, Analytics, and Enterprise Solutions, founded the co ...
An emphasis on emotional depth and cultural nuance within the design process is among the priorities in creative education, ...
Call of Cthulhu's Chaosium and others have condemned 4 Pillar Games' rampant AI use in what it calls a tabletop "historical ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced significant updates to two ...
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli ...
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership ...
Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.
North Sea Port has announced that LanzaTech Global has selected North Sea Port, Ghent, Belgium, as the permanent site for ...
Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results